02:28 AM EDT, 10/19/2026 (MT Newswires) -- British drugmaker GSK's (GSK.L) antibody-drug conjugate risvutatug rezetecan demonstrated "positive anti-tumor activity" in the Embold PanTumour-101 trial involving patients with relapsed, extensive-stage small cell lung cancer. The treatment, also known as Ris-Rez, achieved an objective response rate of 61% at the 8 milligram per kilogram dose, compared with 32% at the 6 mg/kg dose, according to data from the phase 1b dose-optimization portion of the trial released Monday. GSK said the treatment showed a manageable safety profile at both dose levels at a median follow-up of 100.5 days.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.